{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:12:53Z","timestamp":1791123173967,"version":"4.1.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Based on limited data, intravenous immunoglobulins (IVIG) have been proposed as possible last therapeutic option for recurrent pericarditis (RP). The aim of this multicentre registry was to evaluate the efficacy and safety of IVIG in these patients after failure of other medical therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This multicentre cohort study enrolled consecutive patients with RP treated with IVIG. The primary outcome was the pericarditis recurrence rate after treatment with IVIG. A total of 43 patients (median age 41.7 \u00b1 14.4 years, 65.1% women) were included. The median duration of disease was 39 months (19\u201370), and the mean recurrence before IVIG was 5 (4\u20136). Most patients had elevated C-reactive protein (76.7%), pericardial effusion (72.1%), and fever (69.8%). Intravenous immunoglobulins were administered at a dose of 400\u2013500\u2005mg\/kg\/day for 5 consecutive days with repeated cycles, if needed. At discharge, 40 (93%) patients had achieved clinical remission with IVIG. After a mean follow-up of 73 (20\u201384) months, the number of recurrences and the number of emergency department admissions\/year were reduced, respectively, from 1.80 to 0.46 and 0.79 to 0.16 events\/year (P &amp;lt; 0.001). The need for corticosteroid and anakinra use was also reduced significantly by IVIG (respectively, from 72.1 to 19.4%, P &amp;lt; 0.001 and 60.5 to 23.3%, P &amp;lt; 0.02). No difference in baseline characteristics was found between the patients who experienced a recurrence after the IVIG treatment and those who did not. No serious adverse events occurred; only one patient discontinued IVIG due to onset of moderate neutropenia, reversible within a few days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with RP refractory to the conventional therapy, IVIG were efficacious and safe in reducing further recurrences after failure of other conventional medical therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf250","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T07:43:43Z","timestamp":1745567023000},"page":"766-771","source":"Crossref","is-referenced-by-count":6,"title":["Human intravenous immunoglobulins for recurrent pericarditis: a multicentre cohort study"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0008-4630","authenticated-orcid":false,"given":"Valentino","family":"Collini","sequence":"first","affiliation":[{"name":"Cardiology and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, ASUFC, Udine and Department of Medicine, University of Udine , Piazzale Santa Maria della Misericordia 15, 33100 Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Venturelli","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, ASUFC, Udine and Department of Medicine, University of Udine , Piazzale Santa Maria della Misericordia 15, 33100 Udine ,","place":["Italy"]},{"name":"Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan","family":"Berghi","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Andreis","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medical Sciences, Citt\u00e0 della Salute e della Scienza di Torino University Hospital, University of Torino , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"De Biasio","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, ASUFC, Udine and Department of Medicine, University of Udine , Piazzale Santa Maria della Misericordia 15, 33100 Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-5600","authenticated-orcid":false,"given":"Antonio","family":"Brucato","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences \u2018Sacco\u2019, University of Milano , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-9617","authenticated-orcid":false,"given":"George","family":"Lazaros","sequence":"additional","affiliation":[{"name":"First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens , Vas. Sofias 114, 11527 Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-8478","authenticated-orcid":false,"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-0245","authenticated-orcid":false,"given":"Massimo","family":"Imazio","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, ASUFC, Udine and Department of Medicine, University of Udine , Piazzale Santa Maria della Misericordia 15, 33100 Udine ,","place":["Italy"]},{"name":"Department of Medicine (DMED), University of Udine , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2026032619565729800_zwaf250-B1","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC guidelines for the diagnosis and management of pericardial diseases: the Task Force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"2026032619565729800_zwaf250-B2","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa1208536","article-title":"A randomized trial of colchicine for acute pericarditis","volume":"369","author":"Imazio","year":"2013","journal-title":"N Engl J Med"},{"key":"2026032619565729800_zwaf250-B3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/CIRCULATIONAHA.107.761064","article-title":"Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation","volume":"118","author":"Imazio","year":"2008","journal-title":"Circulation"},{"key":"2026032619565729800_zwaf250-B4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-155-7-201110040-00359","article-title":"Colchicine for recurrent pericarditis (CORP): a randomized trial","volume":"155","author":"Imazio","year":"2011","journal-title":"Ann Intern Med"},{"key":"2026032619565729800_zwaf250-B5","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"2026032619565729800_zwaf250-B6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"2026032619565729800_zwaf250-B7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1177\/2047487319879534","article-title":"Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (international Registry of Anakinra for Pericarditis) study","volume":"27","author":"Imazio","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2026032619565729800_zwaf250-B8","doi-asserted-by":"crossref","first-page":"e002599","DOI":"10.1136\/openhrt-2023-002599","article-title":"Efficacy of colchicine in addition to anakinra in patients with recurrent pericarditis","volume":"11","author":"Collini","year":"2024","journal-title":"Open Heart"},{"key":"2026032619565729800_zwaf250-B9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijcard.2020.03.069","article-title":"Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: a pilot observational prospective study","volume":"311","author":"Lazaros","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026032619565729800_zwaf250-B10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijcard.2011.01.027","article-title":"Azathioprine in isolated recurrent pericarditis: a single centre experience","volume":"147","author":"Vianello","year":"2011","journal-title":"Int J Cardiol"},{"key":"2026032619565729800_zwaf250-B11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.amjcard.2013.06.036","article-title":"Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis","volume":"112","author":"Moretti","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026032619565729800_zwaf250-B12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2459\/JCM.0000000000000260","article-title":"Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases","volume":"17","author":"Imazio","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026032619565729800_zwaf250-B13","first-page":"1103","article-title":"New developments in the management of recurrent pericarditis","volume":"39","author":"Imazio","year":"2023","journal-title":"Can J Cardiol"},{"key":"2026032619565729800_zwaf250-B14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1159\/000539069","article-title":"Effects of intravenous immunoglobulins on human innate immune cells: collegium internationale allergologicum update 2024","volume":"185","author":"Jandus","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"key":"2026032619565729800_zwaf250-B15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2015.00469","article-title":"Induction of regulatory T cells by intravenous immunoglobulin: a bridge between adaptive and innate immunity","volume":"6","author":"Kaufman","year":"2015","journal-title":"Front Immunol"},{"key":"2026032619565729800_zwaf250-B16","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jaip.2023.04.002","article-title":"Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions","volume":"11","author":"Bayry","year":"2023","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf250\/63021936\/zwaf250.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/5\/766\/63021936\/zwaf250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/5\/766\/63021936\/zwaf250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:57:04Z","timestamp":1774569424000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/5\/766\/8121192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,4,28]]},"published-print":{"date-parts":[[2026,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf250","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,4,28]]}}}